Effectiveness of lenvatinib plus immune checkpoint inhibitors in primary advanced hepatocellular carcinoma beyond oligometastasis.

Xiao-Hui WangChang-Jun LiuHao-Quan WenXiao-Hui DuanYu-Qing JiaoYu-Jiang LiuMin-Shan ChenKang-Shun ZhuXian-Hai MaoQun-Fang Zhou

Published in: Clinical and translational medicine (2023)

Patients with advanced HCC beyond oligometastasis, simultaneous administration of lenvatinib and PD-1 inhibitor led to significant improvements in survival.

Keyphrases

randomized controlled trial
systematic review
free survival
light emitting